Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Short Chemo Radio Immunotherapy in Follicular Lymphoma Trial of Y-90 ibritumomab tiuxetan (Zevalin®) as therapy for first and second relapse in follicular lymphoma

Trial Profile

Short Chemo Radio Immunotherapy in Follicular Lymphoma Trial of Y-90 ibritumomab tiuxetan (Zevalin®) as therapy for first and second relapse in follicular lymphoma

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Ibritumomab tiuxetan; Prednisolone; Vincristine
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms SCHRIFT
  • Most Recent Events

    • 16 Dec 2021 Status changed to discontinued.
    • 30 Aug 2014 According to United Kingdom Clinical Research Network record the accruel to date is 90%
    • 30 Jan 2014 According to UKCRN the accruel to date is 90%

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top